Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity.
OBJECTIVE
To determine in vivo whether LH supplementation during the late follicular phase induces increased production of ovarian follicle adiponectin in humans.


METHODS
Randomized, double-blind, placebo-controlled study.


METHODS
Academic tertiary care medical center.


METHODS
Twenty infertile, healthy women (aged 18-39 years) undergoing IVF.


METHODS
Administration of recombinant FSH after down-regulation and equal randomization of subjects to receive recombinant LH 75 IU/day or placebo when two or more follicles reached a mean diameter of 14 mm.


METHODS
Follicular fluid (FF) adiponectin levels were measured.


RESULTS
Adiponectin FF levels were significantly higher in the recombinant LH group compared with the placebo group, and these differences were unaltered after correction to estrogen (E) levels and number of follicles in each cycle.


CONCLUSIONS
This is the first demonstration of in vivo induction of adiponectin by gonadotropins in the human ovary. The addition of recombinant LH during the late follicular phase may enhance follicular insulin sensitivity, resulting in decreased androgen levels through a cascade mediated by increased production of adiponectin.
Gutman
Guy
G
Sara Racine IVF Unit, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. gutguy10@yahoo.com
Barak
Vivian
V
Maslovitz
Sharon
S
Amit
Ami
A
Lessing
Joseph B
JB
Geva
Eli
E
D052242:Adiponectin / Q000032:analysis / Q000096:biosynthesis*; D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005307:Fertilization in Vitro; D015571:Follicular Fluid / Q000378:metabolism*; D006801:Humans; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000494:pharmacology*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000494:pharmacology
D052242:Adiponectin; D011994:Recombinant Proteins; D007986:Luteinizing Hormone